what do you do when the bacteria have a resistance to the antibiotics

• Journal Listing
• J Anaesthesiol Clin Pharmacol
• five.33(3); Jul-Sep 2017
• PMC5672523

J Anaesthesiol Clin Pharmacol. 2017 Jul-Sep; 33(3): 300–305.

Action and resistance mechanisms of antibiotics: A guide for clinicians

Garima Kapoor

Department of Microbiology, Gandhi Medical Higher, Bhopal, Madhya Pradesh, India

Saurabh Saigal

¹Department of Trauma and Emergency, AIIMS, Bhopal, Madhya Pradesh, Bharat

Ashok Elongavan

²Department of Disquisitional Intendance Medicine, Columbia Asia Hospital, Bengaluru, Karnataka, Bharat

Abstract

Infections account for a major cause of decease throughout the developing world. This is mainly due to the emergence of newer infectious agents and more specifically due to the appearance of antimicrobial resistance. With time, the bacteria have become smarter and along with it, massive imprudent usage of antibiotics in clinical exercise has resulted in resistance of bacteria to antimicrobial agents. The antimicrobial resistance is recognized as a major trouble in the treatment of microbial infections. The biochemical resistance mechanisms used by bacteria include the following: antibiotic inactivation, target modification, altered permeability, and "bypass" of metabolic pathway. Determination of bacterial resistance to antibiotics of all classes (phenotypes) and mutations that are responsible for bacterial resistance to antibiotics (genetic assay) are helpful. Better understanding of the mechanisms of antibiotic resistance will help clinicians regarding usage of antibiotics in unlike situations. This review discusses the mechanism of activeness and resistance development in normally used antimicrobials.

Keywords: Antibiotics, antimicrobial resistance, bacterial prison cell wall, mechanism of activeness

Introduction

The struggle of mankind against infectious diseases is well known. The discovery of antibiotics led to optimism that infections tin can exist controlled and prevented. However, infections are even so the leading cause of decease in developing earth. This is due to the emergence of new disease, reemergence of diseases in one case controlled and more specifically due to the appearance of antimicrobial resistance. It appears that the emergence of antimicrobial resistance is inevitable to almost every new drug, and it is recognized as a major problem in the treatment of microbial infections in both hospitals and community. This review intends to hash out the machinery of action and resistance development in normally used antimicrobials. For this purpose, nosotros need to know the basic beefcake of bacterial cell, nomenclature of antibiotics based on their mechanism of action, mechanisms of antibiotic resistance, and individual antibiotics with their common mechanism of resistance.

Basic Anatomy of Bacterial Cell

The Gram-positive bacteria consists of cytoplasmic membrane surrounded by a tough and rigid mesh chosen prison cell wall. In dissimilarity, Gram-negative bacteria consist of thin jail cell wall that is surrounded by second lipid membrane called outer membrane (OM). The space betwixt the OM and cytoplasmic membrane is referred equally periplasm [Effigy 1]. The OM is an boosted protective layer in Gram-negative bacteria and prevents many substances from entering into the bacterium. Even so, this membrane contains channels chosen porins, which allow the entry of diverse molecules such equally drugs.[i] The cell wall is a tough layer that gives bacterium a feature shape and prevents it from osmotic and mechanical stresses. The cytoplasmic membrane prevents ions from flowing into or out of the cell and maintains the cytoplasmic and bacterial components in a defined infinite.

Construction of bacterial cell envelope

Classification of Antibiotics on the Basis of Mechanism of Action

The antibiotics are classified on the basis of mechanism of activeness every bit described in Figure 2.

Mechanism of activeness of antibiotics

Antibiotics targeting cell wall

Bacterial cells are surrounded by a prison cell wall made of peptidoglycan, which consists of long saccharide polymers. The peptidoglycan undergoes cantankerous-linking of the glycan strands by the action of transglycosidases, and the peptide chains extend from the sugars in the polymers and course cross links, one peptide to another.[ii] The D-alanyl-alanine portion of peptide chain is cross linked by glycine residues in the presence of penicillin binding proteins (PBPs).[iii] This cross-linking strengthens the prison cell wall. β-lactams and the glycopeptides inhibit cell wall synthesis.

Beta-lactam antibiotics

The main targets of the β-lactam agents are the PBPs. It has been hypothesized that the β-lactam ring mimics the D-alanyl D-alanine portion of peptide concatenation that is normally jump by PBP. The PBP interacts with β-lactam ring and are not available for the synthesis of new peptidoglycan. The disruption of peptidoglycan layer leads to the lysis of bacterium [Figure iii].[4]

Mechanism of action of β-lactam antibiotics

Glycopeptides

The glycopeptides binds to D-alanyl D-alanine portion of peptide side chain of the precursor peptidoglycan subunit. The big drug molecule vancomycin prevents binding of this D-alanyl subunit with the PBP, and hence inhibits cell wall synthesis [Figure three].[4,5]

Inhibitors of protein biosynthesis

First the data in bacterial DNA is used to synthesize an RNA molecule referred to as messenger RNA (m-RNA) a process known as transcription [Figure 4]. So, the macromolecular structure called ribosome synthesizes proteins nowadays in m-RNA, a process chosen translation. Protein biosynthesis is catalyzed by ribosomes and cytoplasmic factors. The bacterial 70S ribosome is composed of two ribonucleoprotein subunits, the 30S and 50S subunits.[6] Antimicrobials inhibit protein biosynthesis by targeting the 30S or 50S subunit of the bacterial ribosome.[7,8]

Site of activeness of protein biosynthesis inhibitors

Inhibitors of 30S subunit

Aminoglycosides

The aminoglycosides (AG's) are positively-charged molecules which adhere to the OM which is negatively charged leading to formation of large pores, and thus permit antibody penetration within the bacterium. The main target of action is bacterial ribosome; to enter, there it must laissez passer through cytoplasmic membrane requiring free energy dependent active bacterial transport machinery, which requires oxygen and an active proton motive force. For these reasons, AG work in aerobic conditions and have poor activeness against anaerobic bacteria. These AG have synergism with those antibiotics, which inhibit cell wall synthesis (such as β-lactam and glycopeptides) as it allows greater penetration of AG within the cell and at low dosages. AG's interact with the 16S r-RNA of the 30S subunit well-nigh the A site through hydrogen bonds. They crusade misreading and premature termination of translation of mRNA.

Tetracyclines

Tetracyclines, such as tetracycline, chlortetracycline, doxycycline, or minocycline, act upon the conserved sequences of the 16S r-RNA of the 30S ribosomal subunit to prevent binding of t-RNA to the A site.[vi,nine]

Inhibitors of 50S subunit

Chloramphenicol

It interacts with the conserved sequences of the peptidyl transferase cavity of the 23S r-RNA of the 50S subunit. Hence, it inhibits the protein synthesis by preventing bounden of t-RNA to the A site of the ribosome.[half dozen,seven]

Macrolides

These affect the early on phase of poly peptide synthesis, namely translocation, by targeting the conserved sequences of the peptidyl transferase heart of the 23S r-RNA of the 50S ribosomal subunit.[half-dozen,9] This results in a premature disengagement of incomplete peptide chains. Macrolides, lincosamides, and streptogramins B show a like machinery of action.

Oxazolidinones

Linezolid is a recently approved member of novel class of antibody of this group which is completely synthetic. Oxazolidinones interfere with protein synthesis at several stages: (i) inhibit poly peptide synthesis by binding to 23Sr RNA of the 50S subunit and (ii) suppress 70S inhibition and interact with peptidyl-t-RNA.[10,11]

Inhibitors of Deoxyribonucleic acid replication

Quinilones

The fluoroquinolones (FQ) inhibit the enzyme bacterial Deoxyribonucleic acid gyrase, which nicks the double-stranded DNA, introduces negative supercoils then reseals the nicked ends. This is necessary to prevent excessive positive supercoiling of the strands when they split to let replication or transcription. The Deoxyribonucleic acid gyrase consists of two A subunits and two B subunits. A subunit carries out the nicking of DNA, B subunit introduces negative supercoils, and then A subunit reseal the strands. The FQ's bind to A subunit with loftier affinity and interfere with its strand cut and resealing function. In Gram-positive leaner, the major target of action is topoisomerase IV which nicks and separate's daughter Deoxyribonucleic acid strand later on DNA replication. Greater affinity for this enzyme may confer higher dominance against Gram-positive leaner. In place of Dna gyrase or topoisomerase IV, mammalian cells possess topoisomerase II, which has very depression affinity for FQ-hence low toxicity to cells.[half-dozen,9,12]

Folic acrid metabolism inhibitors

Sulfonamides and trimethoprim

Each of these drugs inhibits distinct steps in folic acid metabolism. A combination of sulpha drugs and trimethoprim interim at distinct steps on the same biosynthetic pathway shows synergy and a reduced mutation rate for resistance.[half dozen] Sulfonamides inhibit dihydropteroate synthase in a competitive style with higher analogousness for the enzyme than the natural substrate, p-amino benzoic acid. Agents such as trimethoprim act at a afterwards stage of folic acid synthesis and inhibit the enzyme dihydrofolate reductase.[6]

Mechanisms of Antimicrobial Resistance

Prevention of accumulation of antimicrobials either by decreasing uptake or increasing efflux of the antimicrobial from the cell i.e Changes in outer membrane permeability

Drug molecules to a cell tin be transferred by diffusion through porins, diffusion through the bilayer and by self-uptake. The porin channels are located in OM of Gram-negative bacteria. The minor hydrophilic molecules (β-lactams and quinolones) can cantankerous the OM only through porins. The decrease in number of porin channels, lead to decreased entry of β-lactam antibiotics and FQ into the cell, hence resistance to these classes of antibiotics. Acquired resistance to all antibiotic classes in Pseudomonas aeruginosa is due to low-OM permeability.

Efflux pumps

Membrane proteins that consign antibiotics from the jail cell and maintain their low-intracellular concentrations are called efflux pumps.[4] At the aforementioned speed, where these antimicrobials are inbound the cell, efflux mechanisms are pumping them out again, before they reach their target.[ix] These pumps are nowadays in the cytoplasmic membrane, unlike porins which are present in OM. Antibiotics of all classes except polymyxin are susceptible to the activation of efflux systems.[thirteen] Efflux pumps can be specific to antibiotics. Most of them are multidrug transporters that are capable to pump a wide range of unrelated antibiotics – macrolides, tetracyclines, and FQ – and thus significantly contribute to multidrug resistant organisms.[4]

Modification of target molecule

Natural variations or caused changes in the target sites of antimicrobials that forestall drug binding is a common mechanism of resistance. Target site changes ofttimes result from spontaneous mutation of a bacterial factor on the chromosome. Since antibody interaction with target molecule is generally quite specific, pocket-size alteration of the target molecule can have of import result on antibiotic binding.

1. Alteration in the 30S subunit or 50S subunit: Of the ribosome leads to resistance to drugs that bear upon the protein synthesis, i.due east., macrolides, tetracycline, chloramphenicol, and AG's. AG's demark to the 30S ribosomal subunit,[xiii] whereas chloramphenicol, macrolides, lincosamides, and streptogramin B demark to the 50S ribosomal subunit to suppress poly peptide synthesis[14]

2. Alteration in PBP: Modification of the PBP is a favored mechanism of resistance to Gram-positive leaner, whereas production of β-lactamases is a mechanism for the development of resistance to Gram-negative bacteria. The presence of mutation in penicillin-binding poly peptide leads to a reduced affinity to β-lactam antibiotics. The resistance of Enterococcus faecium to ampicillin and Streptococcus pneumoniae to penicillin is past this mechanism. Similarly, in Staphylococcus aureus, the resistance to methicillin and oxacillin is associated with integration of a mobile genetic chemical element – "staphylococcal cassette chromosome mec" – into the chromosome of Southward.aureus that contains resistance cistron mec A.[four,15,sixteen] mec A gene encodes PBP2a poly peptide, a new penicillin-binding poly peptide, that is required to modify a native staphylococcal PBP. PBP2a shows a high resistance to β-lactam antibiotics. Southward. aureus strains resistant to methicillin tin can be cross resistant to all β-lactam antibiotics, streptomycin, and tetracycline and in some cases to erythromycin[five]

3. Altered jail cell wall precursors: Cell wall synthesis in Gram-positive bacteria can be inhibited by glycopeptides, east.g., vancomycin or teicoplanin, past their binding to D-alanyl-D-alanine residues of peptidoglycan precursors. D-alanyl-alanine is inverse to D-alanyl-lactate as a result of which glycopeptides do not cantankerous link with them, hence resistance to them develops.[4,5] E. faecium and Enterococcus faecalis strains have loftier resistance to vancomycin and teicoplanin (Van A-type resistance). Van B and Van C type resistance prove resistance to vancomycin merely is sensitive to teicoplanin[17]

4. Mutated-Dna gyrase and topoisomerase IV leads to FQ resistance: Quinolones bind to DNA gyrase A subunit. The mechanism of resistance involves the modification of two enzymes: Dna gyrase (coded by genes gyr A and gyr B) and topoisomerase IV (coded past genes par C and par East).[18] Mutations in genes gyr A and par C leads to the replication failure and equally a effect FQ cannot bind

5. Ribosomal protection mechanisms imparting resistance to tetracyclines

6. RNA polymerase mutations conferring resistance to rifampicin.

Antibiotic inactivation

There are three chief enzymes that inactivate antibiotics such as β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferases (AACs).[nineteen]

Beta-lactamases

β-lactamases hydrolyze nearly all β-lactams that take ester and amide bond, e.g., penicillins, cephalosporins, monobactams, and carbapenems. Nigh 300 β-lactamases are known till date. β-lactamases are broadly prevalent enzymes that are classified using 2 main classification systems: Ambler (structural) and Bush-league–Jacoby–Medeiros (functional).[15] Ambler classification system is described below:

1. Form A β-lactamases: Also referred as penicillinase; these are clavulanic acrid susceptible. Two usually encountered Class A β-lactamases found in members of Enterobacteriaceae are designated as TEM-1, SHV-i. These are penicillinase with little or no activity against cephalosporin.[20] These are progenitors of extended-spectrum β-lactamases (ESBL). ESBL are enzymes that have changed substrate contour because of amino-acrid commutation allowing hydrolysis of most cephalosporins. ESBL are resistant to penicillins, third-generation cephalosporins (due east.g., ceftazidime, cefotaxime, ceftriaxone), aztreonam, cefamandole, cefoperazone, only are sensitive to methoxy-cephalosporins, eastward.g., cephamycins and carbapenems and are inhibited past inhibitors of β-lactamases, e.thousand., clavulanic acrid, sulbactam, or tazobactam[21,22,23]

2. Grade B β-lactamases: These are metallo-β-lactamases. These require enzymes such equally zinc or heavy metals for catalysis and their action is inhibited by chelating agents. These classes of enzymes are resistant to inactivation by clavulanate, sulbactam, aztreonam, and carbapenems. E.g., New Delhi metallo-β-lactamase[24]

3. Course C β-lactamases: These are too chosen cephalosporinases. These are produced past all Gram-negative leaner with exception of Salmonella and Klebsiella. Class C hydrolyzes cephalosporins including extended spectrum cephalosporins, in comparing to class A β-lactamases, these take large cavities, and every bit a outcome, they are able to bind the bulky extended spectrum penicillin. An example of this type is Amp C β-lactamases. This class of enzymes is resistant to all β-lactams except carbapenems. They are non inhibited past clavulanate[25,26]

4. Class D β-lactamases: These are oxacillin hydrolyzing enzymes – institute most usually in Enterobacteriaceae and in P. aeruginosa. Oxacillin-hydrolyzing enzymes confer resistance to penicillin, cloxacillin, oxacillin, and methicillin. They are weakly inhibited by clavulanic acid but are inhibited past sodium chloride.[27]

Aminoglycoside modifying enzymes (Age'southward)

AG are neutralized past specific enzymes: Phosphoryl-transferases, nucleotidyl-transferases or adenylyl-transferases, and AACs. These aminoglycoside-modifying enzymes (AMEs) reduce affinity of a modified molecule, impede binding to the 30S ribosomal subunit,[28] and provide extended spectrum resistance to AG's and FQ.[29] AMEs are identified in Southward. aureus, E. faecalis, and S. pneumoniae strains.

Chloramphenicol-acetyl-transferases

Few Gram-positive and Gram-negative leaner and some of Haemophilus influenzae strains are resistant to chloramphenicol, and they have an enzyme chloramphenicol transacetylase that acetylates hydroxyl groups of chloramphenicol. Modified chloramphenicol is unable to bind to a ribosomal 50S subunit properly.[xxx]

Resistance mechanism of diverse antibiotics is described in Table 1.

Table ane

Resistance machinery of individual antibiotics

Decision

The discovery of antibiotics led to sigh of relief, that now no leaner volition reside in this planet. With fourth dimension, the bacteria have become smarter, and forth with it, massive usage of antibiotics in clinical practice has resulted in resistance of bacteria to antimicrobial agents. The following biochemical types of resistance mechanisms are used by bacteria: Antibiotic inactivation, target modification, contradistinct permeability, and "bypass" metabolic pathway. Determination of bacterial resistance to antibiotics of all classes (phenotypes) and mutations that are responsible for bacterial resistance to antibiotics (genetic analysis) are helpful. Better agreement of the mechanisms of antibiotic resistance, volition help clinicians regarding usage of antibiotics in different situations.

Fiscal support and sponsorship

Nix.

Conflicts of involvement

There are no conflicts of involvement.

References

one. Hauser AR, editor. Cell envelope. Antibody Basic for Clinicians. 2nd ed. New Delhi: Wolters Kluwer (India) Pvt. Ltd; 2015. pp. three–5. [Google Scholar]

two. Kahne D, Leimkuhler C, Lu W, Walsh C. Glycopeptide and lipoglycopeptide antibiotics. Chem Rev. 2005;105:425–48. [PubMed] [Google Scholar]

3. Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis. 1989;8:943–50. [PubMed] [Google Scholar]

4. Džidic Southward, Šuškovic J, Kos B. Antibiotic resistance mechanisms in bacteria: Biochemical and genetic aspects. Nutrient Technol Biotechnol. 2008;46:eleven–21. [Google Scholar]

5. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-wellness threat. Lancet. 2006;368:874–85. [PubMed] [Google Scholar]

6. Yoneyama H, Katsumata R. Antibiotic resistance in leaner and its future for novel antibiotic development. Biosci Biotechnol Biochem. 2006;70:1060–75. [PubMed] [Google Scholar]

7. Vannuffel P, Cocito C. Mechanism of action of streptogramins and macrolides. Drugs. 1996;51(Suppl 1):20–30. [PubMed] [Google Scholar]

8. Johnston NJ, Mukhtar TA, Wright GD. Streptogramin antibiotics: Way of activeness and resistance. Curr Drug Targets. 2002;3:335–44. [PubMed] [Google Scholar]

9. Wise R. A review of the mechanisms of activeness and resistance of antimicrobial agents. Tin Respir J. 1999;half-dozen(Suppl A):20A–2A. [PubMed] [Google Scholar]

10. Lambert PA. Bacterial resistance to antibiotics: Modified target sites. Adv Drug Deliv Rev. 2005;57:1471–85. [PubMed] [Google Scholar]

eleven. Bozdogan B, Appelbaum PC. Oxazolidinones: Activity, fashion of action, and mechanism of resistance. Int J Antimicrob Agents. 2004;23:113–9. [PubMed] [Google Scholar]

12. Higgins PG, Fluit Air conditioning, Schmitz FJ. Fluoroquinolones: Structure and target sites. Curr Drug Targets. 2003;4:181–90. [PubMed] [Google Scholar]

thirteen. Lambert PA. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J R Soc Med. 2002;95(Suppl 41):22–six. [PMC gratis article] [PubMed] [Google Scholar]

xiv. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Med. 2006;119(six Suppl 1):S3–10. [PubMed] [Google Scholar]

15. Alekshun MN, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. Jail cell. 2007;128:1037–l. [PubMed] [Google Scholar]

16. Hiramatsu Grand, Cui L, Kuroda G, Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol. 2001;9:486–93. [PubMed] [Google Scholar]

17. Giedraitiene A, Vitkauskiene A, Naginiene R, Pavilonis A. Antibiotic resistance mechanisms of clinically important leaner. Medicina (Kaunas) 2011;47:137–46. [PubMed] [Google Scholar]

eighteen. Kim YH, Cha CJ, Cerniglia CE. Purification and characterization of an erythromycin esterase from an erythromycin-resistant Pseudomonas sp. FEMS Microbiol Lett. 2002;210:239–44. [PubMed] [Google Scholar]

19. Dockrell HM, Goering RV, Roitt I, Wakelin D, Zuckerman K. In: Attacking the enemy: Antimicrobial agents and chemotherapy. Medical Microbiology. Mims C, Dockrell HM, Goering RV, Roitt I, Wakelin D, Zuckerman Grand, editors. Netherlands: Elsevier Mosby; 2004. pp. 473–507. [Google Scholar]

xx. Rice LB, Sahm D, Bonomo R. Mechanisms of resistance to antibacterial agents. In: Murray PR, editor. Manual of Clinical Microbiology. 8th ed. Washington, DC: ASM Press; 2003. pp. 1084–7. [Google Scholar]

21. Jacoby GA, Munoz-Price LS. The new beta-lactamases. Northward Engl J Med. 2005;352:380–91. [PubMed] [Google Scholar]

22. Ma 50, Chang FY, Fung CP, Chen TL, Lin JC, Lu PL, et al. Variety of TEM-, SHV-, and CTX-Thou-blazon beta-lactamases nowadays in contempo clinical isolates of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae from Taiwan. Microb Drug Resist. 2005;eleven:31–9. [PubMed] [Google Scholar]

23. Bonnet R. Growing grouping of extended-spectrum beta-lactamases: The CTX-M enzymes. Antimicrob Agents Chemother. 2004;48:one–14. [PMC gratis commodity] [PubMed] [Google Scholar]

24. Rasmussen BA, Bush-league K. Carbapenem-hydrolyzing beta-lactamases. Antimicrob Agents Chemother. 1997;41:223–32. [PMC free commodity] [PubMed] [Google Scholar]

25. Crichlow GV, Kuzin AP, Nukaga M, Mayama Thousand, Sawai T, Knox JR. Construction of the extended-spectrum class C beta-lactamase of Enterobacter cloacae GC1, a natural mutant with a tandem tripeptide insertion. Biochemistry. 1999;38:10256–61. [PubMed] [Google Scholar]

26. Lobkovsky E, Billings EM, Moews PC, Rahil J, Pratt RF, Knox JR. Crystallographic structure of a phosphonate derivative of the Enterobacter cloacae P99 cephalosporinase: Mechanistic interpretation of a beta-lactamase transition-land analog. Biochemistry. 1994;33:6762–72. [PubMed] [Google Scholar]

27. Naas T, Nordmann P. OXA-type beta-lactamases. Curr Pharm Des. 1999;5:865–79. [PubMed] [Google Scholar]

28. Strateva T, Yordanov D. Pseudomonas aeruginosa – A phenomenon of bacterial resistance. J Med Microbiol. 2009;58(Pt ix):1133–48. [PubMed] [Google Scholar]

29. Maurice F, Broutin I, Podglajen I, Benas P, Collatz E, Dardel F. Enzyme structural plasticity and the emergence of broad-spectrum antibiotic resistance. EMBO Rep. 2008;9:344–9. [PMC costless article] [PubMed] [Google Scholar]

30. Tolmasky ME. Bacterial resistance to aminoglycosides and beta-lactams: The Tn1331 transposon paradigm. Front Biosci. 2000;5:D20–nine. [PubMed] [Google Scholar]

---

Articles from Journal of Anaesthesiology, Clinical Pharmacology are provided here courtesy of Wolters Kluwer -- Medknow Publications

---

giordanomageting.blogspot.com

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672523/

Share this post